A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of ...

Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosisOngoing discussions with ...

Rival European pharma giants Sanofi and GSK have both forged new partnerships to bolster their preclinical research. | Rival ...

Sanofi ($SNYNF) announced an update on their ongoing clinical study. Study Overview: Sanofi is conducting a Phase 2 clinical trial titled A ...

Sanofi is expanding options for those with hemophilia with its new treatment, Qfitlia (fitusiran). Approved this year, ...

Sanofi (NASDAQ:SNY) is among the cheap healthcare stocks to buy heading into 2026. As of December 7, Sanofi (NASDAQ:SNY) has ...

Sanofi (SNY) has received Chinese regulatory approval for two rare hematology drugs, Qfitlia and Cablivi, significantly ...

Paris: French multinational pharmaceutical giant, Sanofi, has announced the completion of its acquisition of Vicebio Ltd.This ...

Sanofi SA’s Paris headquarters were raided Tuesday by French authorities as part of a tax fraud investigation into a financing deal provided by Societe Generale SA.

Two treatments for both chronic and acute conditions, Qfitlia and Cablivi, have been approved in China.

Sanofi secures China approvals for Qfitlia and Cablivi, expanding its rare hematology portfolio with new options for ...

In this morning's Pharmalittle roundup, we're reading about FDA scrutiny of RSV therapies, an AI tool for clinical trials, ...